OncLive TV

Tony S.K. Mok, BMSc, MD, FRCP(C), FHKCP, FHKAM, FASCO, discusses first-line treatment decision-making for patients with BRAF-mutant non–small cell lung cancer.

Shyam A. Patel, MD, PhD, discusses the threshold of p53 IHC positivity best correlating with multi-hit TP53 mutational status in MDS and AML.

Jonathan M. Gerber, MD, discusses the potential implementation of p53 IHC testing for MDS and AML in regions with limited access to NGS.

Prerna Mewawalla, MD, explains the roles of cilta-cel and ide-cel in clinical practice for the treatment of relapsed/refractory multiple myeloma.

Jorge Nieva, MD, discusses matched-adjusted indirect comparison data evaluating crizotinib vs alectinib, brigatinib, and lorlatinib in ALK-positive NSCLC.

Sandip P. Patel, MD, discusses toxicities associated with the use of immunotherapy-based combination regimens in patients with advanced NSCLC.

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Cyrus M. Khan, MD, discusses how zanubrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses eliminating surgery for select patients with a pCR after neoadjuvant therapy for early breast cancer.

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Jessica Donington, MD, MSCR, discusses how updated data with perioperative nivolumab in NSCLC may affect future surgical decision-making.

Stefano Luminari, MD, details the safety profile of odronextamab for the treatment of patients with relapsed/refractory follicular lymphoma.

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.

Piotr Rutkowski, MD, discusses a trial evaluating the nivolumab biosimilar JPB898 plus ipilimumab in stage III or metastatic stage IV melanoma.

Rami Komrokji, MD, shares advice on how to integrate imetelstat into clinical practice for transfusion-dependent lower-risk myelodysplastic syndromes.

Darren Pan, MD, outlines late-onset toxicities related to CAR T-cell therapies in multiple myeloma and their management.

Maurie Markman, MD, discusses future research considerations in gynecologic oncology.

Lydia Scarfò, MD, discusses future research directions for BGB-16673 in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Sharlene Gill, MD, MPH, MBA, FRCPC, highlights the importance of considering patients’ concerns ahead of treatment decision-making for advanced CRC.

Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Luke Maese, DO, discusses how the evolution of AYA and adult ALL management may be inspired by treatment protocols used in the pediatric population.

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

John Sfakianos, MD, shared findings from an analysis of mitomycin intravesical solution from the phase 3 ENVISION trial in recurrent NMIBC.

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Richard S. Finn, MD, discusses the background of the MORPHEUS-Liver trial of tiragolumab plus atezolizumab and bevacizumab in HCC.